Review



endothelial lined blood vessel marker  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bioss endothelial lined blood vessel marker
    In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in 4T1 in situ tumor-bearing Balb/c mice. a Scheme of 4T1 in situ tumor-bearing mice model establishment and treatment procedure. b Excised tumors from mice in each group. c Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. d The excised tumor volumes of mice from each group. n = 6 per group. e The excised tumor weights of mice from each group. n = 6 per group. f H&E staining of 4T1 tumors from different treatment groups. IHC staining of 4T1 tumors from different treatment groups for cell proliferation using Ki67 and for <t>endothelial</t> vessels using <t>CD34.</t> Scale bars: 100 μm. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns means no statistical significance
    Endothelial Lined Blood Vessel Marker, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/endothelial+lined+blood+vessel+marker/pmc11920195-498-8-14?v=Bioss
    Average 94 stars, based on 21 article reviews
    endothelial lined blood vessel marker - by Bioz Stars, 2026-07
    94/100 stars

    Images

    1) Product Images from "Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies"

    Article Title: Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies

    Journal: Signal Transduction and Targeted Therapy

    doi: 10.1038/s41392-025-02186-y

    In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in 4T1 in situ tumor-bearing Balb/c mice. a Scheme of 4T1 in situ tumor-bearing mice model establishment and treatment procedure. b Excised tumors from mice in each group. c Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. d The excised tumor volumes of mice from each group. n = 6 per group. e The excised tumor weights of mice from each group. n = 6 per group. f H&E staining of 4T1 tumors from different treatment groups. IHC staining of 4T1 tumors from different treatment groups for cell proliferation using Ki67 and for endothelial vessels using CD34. Scale bars: 100 μm. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns means no statistical significance
    Figure Legend Snippet: In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in 4T1 in situ tumor-bearing Balb/c mice. a Scheme of 4T1 in situ tumor-bearing mice model establishment and treatment procedure. b Excised tumors from mice in each group. c Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. d The excised tumor volumes of mice from each group. n = 6 per group. e The excised tumor weights of mice from each group. n = 6 per group. f H&E staining of 4T1 tumors from different treatment groups. IHC staining of 4T1 tumors from different treatment groups for cell proliferation using Ki67 and for endothelial vessels using CD34. Scale bars: 100 μm. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns means no statistical significance

    Techniques Used: In Vivo, In Situ, Staining, Immunohistochemistry

    In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in the PDX TNBC models. a Scheme of PDX model establishment and treatment procedure. b Tumor growth curves of the PDX mouse models. n = 6 per group. c Image of excised tumors after treatment on day 38. d Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. e Excised tumor volume of different treatment groups. n = 6 per group. f Excised tumor weight of different treatment groups. n = 6 per group. g Ki67 and CD34 IHC staining of tumors from mice administered various treatments. n = 3 per group. Scale bars: 100 μm. h The IHC quantification results in each treatment group. n = 3 per group. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001
    Figure Legend Snippet: In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in the PDX TNBC models. a Scheme of PDX model establishment and treatment procedure. b Tumor growth curves of the PDX mouse models. n = 6 per group. c Image of excised tumors after treatment on day 38. d Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. e Excised tumor volume of different treatment groups. n = 6 per group. f Excised tumor weight of different treatment groups. n = 6 per group. g Ki67 and CD34 IHC staining of tumors from mice administered various treatments. n = 3 per group. Scale bars: 100 μm. h The IHC quantification results in each treatment group. n = 3 per group. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001

    Techniques Used: In Vivo, Immunohistochemistry



    Similar Products

    endothelial lined blood vessel marker  (Bioss)
    94
    Bioss endothelial lined blood vessel marker
    In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in 4T1 in situ tumor-bearing Balb/c mice. a Scheme of 4T1 in situ tumor-bearing mice model establishment and treatment procedure. b Excised tumors from mice in each group. c Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. d The excised tumor volumes of mice from each group. n = 6 per group. e The excised tumor weights of mice from each group. n = 6 per group. f H&E staining of 4T1 tumors from different treatment groups. IHC staining of 4T1 tumors from different treatment groups for cell proliferation using Ki67 and for <t>endothelial</t> vessels using <t>CD34.</t> Scale bars: 100 μm. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns means no statistical significance
    Endothelial Lined Blood Vessel Marker, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/endothelial+lined+blood+vessel+marker/pmc11920195-498-8-14?v=Bioss
    Average 94 stars, based on 1 article reviews
    endothelial lined blood vessel marker - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    endothelial-lined blood vessel marker cd34 et1606-11 antibody  (Huabio Inc)
    90
    Huabio Inc endothelial-lined blood vessel marker cd34 et1606-11 antibody
    In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in 4T1 in situ tumor-bearing Balb/c mice. a Scheme of 4T1 in situ tumor-bearing mice model establishment and treatment procedure. b Excised tumors from mice in each group. c Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. d The excised tumor volumes of mice from each group. n = 6 per group. e The excised tumor weights of mice from each group. n = 6 per group. f H&E staining of 4T1 tumors from different treatment groups. IHC staining of 4T1 tumors from different treatment groups for cell proliferation using Ki67 and for <t>endothelial</t> vessels using <t>CD34.</t> Scale bars: 100 μm. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns means no statistical significance
    Endothelial Lined Blood Vessel Marker Cd34 Et1606 11 Antibody, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/endothelial+lined+blood+vessel+marker/pmc11920195-480-21-27?v=Huabio+Inc
    Average 90 stars, based on 1 article reviews
    endothelial-lined blood vessel marker cd34 et1606-11 antibody - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in 4T1 in situ tumor-bearing Balb/c mice. a Scheme of 4T1 in situ tumor-bearing mice model establishment and treatment procedure. b Excised tumors from mice in each group. c Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. d The excised tumor volumes of mice from each group. n = 6 per group. e The excised tumor weights of mice from each group. n = 6 per group. f H&E staining of 4T1 tumors from different treatment groups. IHC staining of 4T1 tumors from different treatment groups for cell proliferation using Ki67 and for endothelial vessels using CD34. Scale bars: 100 μm. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns means no statistical significance

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies

    doi: 10.1038/s41392-025-02186-y

    Figure Lengend Snippet: In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in 4T1 in situ tumor-bearing Balb/c mice. a Scheme of 4T1 in situ tumor-bearing mice model establishment and treatment procedure. b Excised tumors from mice in each group. c Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. d The excised tumor volumes of mice from each group. n = 6 per group. e The excised tumor weights of mice from each group. n = 6 per group. f H&E staining of 4T1 tumors from different treatment groups. IHC staining of 4T1 tumors from different treatment groups for cell proliferation using Ki67 and for endothelial vessels using CD34. Scale bars: 100 μm. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns means no statistical significance

    Article Snippet: Labeling proliferation marker (Ki67, bsm-60738R, Bioss USA) and endothelial-lined blood vessel marker (CD34, bs-8996R, Bioss USA) antibodies were used for IHC analyses.

    Techniques: In Vivo, In Situ, Staining, Immunohistochemistry

    In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in the PDX TNBC models. a Scheme of PDX model establishment and treatment procedure. b Tumor growth curves of the PDX mouse models. n = 6 per group. c Image of excised tumors after treatment on day 38. d Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. e Excised tumor volume of different treatment groups. n = 6 per group. f Excised tumor weight of different treatment groups. n = 6 per group. g Ki67 and CD34 IHC staining of tumors from mice administered various treatments. n = 3 per group. Scale bars: 100 μm. h The IHC quantification results in each treatment group. n = 3 per group. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies

    doi: 10.1038/s41392-025-02186-y

    Figure Lengend Snippet: In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in the PDX TNBC models. a Scheme of PDX model establishment and treatment procedure. b Tumor growth curves of the PDX mouse models. n = 6 per group. c Image of excised tumors after treatment on day 38. d Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. e Excised tumor volume of different treatment groups. n = 6 per group. f Excised tumor weight of different treatment groups. n = 6 per group. g Ki67 and CD34 IHC staining of tumors from mice administered various treatments. n = 3 per group. Scale bars: 100 μm. h The IHC quantification results in each treatment group. n = 3 per group. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001

    Article Snippet: Labeling proliferation marker (Ki67, bsm-60738R, Bioss USA) and endothelial-lined blood vessel marker (CD34, bs-8996R, Bioss USA) antibodies were used for IHC analyses.

    Techniques: In Vivo, Immunohistochemistry

    In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in 4T1 in situ tumor-bearing Balb/c mice. a Scheme of 4T1 in situ tumor-bearing mice model establishment and treatment procedure. b Excised tumors from mice in each group. c Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. d The excised tumor volumes of mice from each group. n = 6 per group. e The excised tumor weights of mice from each group. n = 6 per group. f H&E staining of 4T1 tumors from different treatment groups. IHC staining of 4T1 tumors from different treatment groups for cell proliferation using Ki67 and for endothelial vessels using CD34. Scale bars: 100 μm. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns means no statistical significance

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies

    doi: 10.1038/s41392-025-02186-y

    Figure Lengend Snippet: In vivo anti-tumor efficacy of photodynamic gel-bombs (DCM@OPR) in 4T1 in situ tumor-bearing Balb/c mice. a Scheme of 4T1 in situ tumor-bearing mice model establishment and treatment procedure. b Excised tumors from mice in each group. c Relative tumor volumes over time in mice from different treatment groups. n = 6 per group. d The excised tumor volumes of mice from each group. n = 6 per group. e The excised tumor weights of mice from each group. n = 6 per group. f H&E staining of 4T1 tumors from different treatment groups. IHC staining of 4T1 tumors from different treatment groups for cell proliferation using Ki67 and for endothelial vessels using CD34. Scale bars: 100 μm. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns means no statistical significance

    Article Snippet: As described in the previous study, , IHC and IF analyses were performed by labeling proliferation marker (Ki67, HA721115, HUABIO) and endothelial-lined blood vessel marker (CD34, ET1606-11, HUABIO) antibodies.

    Techniques: In Vivo, In Situ, Staining, Immunohistochemistry